Regeneron Buys 23andMe’s DNA Data for $256M After Bankruptcy
Regeneron acquires 23andMe’s genetic data for $256M after bankruptcy, raising questions about data privacy and future drug research.
Matilda
Regeneron Buys 23andMe’s DNA Data for $256M After Bankruptcy What happened to 23andMe, and why did Regeneron buy it? In a major development for the biotech and pharmaceutical sectors, Regeneron Pharmaceuticals has agreed to purchase 23andMe's genetic testing services and vast customer data for $ 256 million. The acquisition comes after 23andMe filed for bankruptcy in March 2025, following a high- profile data breach that compromised sensitive genetic and personal information of nearly 7 million users. This deal has sparked intense interest and concern, particularly among those asking: Is my DNA data safe? and What will Regeneron do with 23andMe’s data? Image Credits: Gabe Ginsberg/Getty Images for LARAS Regeneron, a leading pharmaceutical company known for cutting- edge drug development and high- ROI medical innovations, secured the winning bid during a court- supervised bankruptcy auction. The acquisition includes 23andMe’s genomic database of over 15 million users— considered one of the largest private DNA collections in the world. According to Rege…